Adaptive Biotechnologies (NASDAQ: ADPT) revenue
Adaptive Biotechnologies reported revenue of $277.0m for fiscal 2025, 54.8% more than in fiscal 2024 ($179.0m). Since fiscal 2018 its revenue has grown by 397.6%, an average growth of 25.8% a year.
Adaptive Biotechnologies has grown its revenue for 2 years in a row, and fiscal 2025 is the highest of its 8 fiscal years on record. The biggest drop was in fiscal 2023, −8.1%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $277.0m | +54.8% | −$57.1m | −20.6% |
| 2024 | $179.0m | +5.1% | −$162.5m | −90.8% |
| 2023 | $170.3m | −8.1% | −$227.0m | −133.3% |
| 2022 | $185.3m | +20.1% | −$200.2m | −108.0% |
| 2021 | $154.3m | +56.9% | −$209.0m | −135.4% |
| 2020 | $98.4m | +15.6% | −$152.8m | −155.3% |
| 2019 | $85.1m | +52.8% | −$78.4m | −92.1% |
| 2018 | $55.7m | — | −$49.8m | −89.4% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Adaptive Biotechnologies revenue compared with its sector
By revenue for its latest fiscal year, Adaptive Biotechnologies ranks 225th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Adaptive Biotechnologies, 54.8%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 223rd | Xeris Biopharma | $291.8m | 43.7% |
| 224th | Aurinia Pharmaceuticals | $283.1m | 20.4% |
| 225th | Adaptive Biotechnologies | $277.0m | 54.8% |
| 226th | Vericel | $276.3m | 16.5% |
| 227th | Harrow | $272.3m | 36.4% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Adaptive Biotechnologies
- How much revenue did Adaptive Biotechnologies make in fiscal 2025?
- Adaptive Biotechnologies reported revenue of $277.0m for fiscal 2025, compared with $179.0m in fiscal 2024.
- How much has the revenue of Adaptive Biotechnologies grown?
- Between fiscal 2018 and fiscal 2025 it went from $55.7m to $277.0m: 397.6% more, an average growth of 25.8% a year.
- What was the best year for revenue at Adaptive Biotechnologies?
- Of its last 8 fiscal years, fiscal 2025, with $277.0m.
- Where does Adaptive Biotechnologies rank in its sector by revenue?
- It ranks 225th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Adaptive Biotechnologies come from?
- From the annual report (Form 10-K) that Adaptive Biotechnologies files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Adaptive Biotechnologies files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018. More on Adaptive Biotechnologies: the Adaptive Biotechnologies page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.